NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.50 Consensus Target Price from Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $15.00.

Several research analysts have commented on NPCE shares. JPMorgan Chase & Co. raised their price objective on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Wells Fargo & Company lowered their price objective on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th.

NeuroPace Trading Up 1.9 %

NPCE opened at $11.35 on Friday. NeuroPace has a one year low of $5.45 and a one year high of $18.15. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The stock has a market cap of $338.77 million, a price-to-earnings ratio of -11.35 and a beta of 2.05. The stock’s 50 day moving average price is $9.20 and its 200-day moving average price is $7.84.

NeuroPace (NASDAQ:NPCE) last released its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. The business had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same quarter last year, the firm posted ($0.28) earnings per share. On average, equities analysts forecast that NeuroPace will post -1 EPS for the current year.

Insiders Place Their Bets

In other NeuroPace news, major shareholder Ltd. Kck sold 4,031 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $6.54, for a total transaction of $26,362.74. Following the transaction, the insider now owns 5,521,874 shares in the company, valued at approximately $36,113,055.96. This represents a 0.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 257,590 shares of company stock valued at $1,437,916. 22.20% of the stock is currently owned by corporate insiders.

Institutional Trading of NeuroPace

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Financial Advocates Investment Management increased its holdings in NeuroPace by 20.0% in the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock worth $125,000 after buying an additional 3,000 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after purchasing an additional 6,181 shares during the last quarter. XTX Topco Ltd lifted its position in NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after purchasing an additional 8,643 shares during the period. State Street Corp boosted its holdings in NeuroPace by 9.1% in the third quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after purchasing an additional 12,912 shares during the last quarter. Finally, Rhumbline Advisers purchased a new stake in NeuroPace in the second quarter valued at $111,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.